Douglas S. Goodin

17.3k total citations · 3 hit papers
150 papers, 10.3k citations indexed

About

Douglas S. Goodin is a scholar working on Pathology and Forensic Medicine, Cognitive Neuroscience and Rheumatology. According to data from OpenAlex, Douglas S. Goodin has authored 150 papers receiving a total of 10.3k indexed citations (citations by other indexed papers that have themselves been cited), including 79 papers in Pathology and Forensic Medicine, 39 papers in Cognitive Neuroscience and 31 papers in Rheumatology. Recurrent topics in Douglas S. Goodin's work include Multiple Sclerosis Research Studies (77 papers), EEG and Brain-Computer Interfaces (25 papers) and Systemic Lupus Erythematosus Research (19 papers). Douglas S. Goodin is often cited by papers focused on Multiple Sclerosis Research Studies (77 papers), EEG and Brain-Computer Interfaces (25 papers) and Systemic Lupus Erythematosus Research (19 papers). Douglas S. Goodin collaborates with scholars based in United States, Germany and Canada. Douglas S. Goodin's co-authors include Michael J. Aminoff, Kenneth C. Squires, Arnold Starr, A. Starr, Bruce Cree, Fred Lublin, Daniel Pelletier, Emmanuelle Waubant, Anthony T. Reder and Volker Knappertz and has published in prestigious journals such as Nature, PLoS ONE and Brain.

In The Last Decade

Douglas S. Goodin

146 papers receiving 9.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

2014 664 citations Peter A. Calabresi, Douglas S. Goodin et al. profile →
Disease modifying therapies in multiple sclerosis: Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines [RETIRED]

2002 603 citations Douglas S. Goodin, Fred Lublin et al. Neurology profile →
Age-related variations in evoked potentials to auditory stimuli in normal human subjects

1978 520 citations Douglas S. Goodin et al. Electroencephalography and Clinical Neurophysiology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Douglas S. Goodin United States	56	5.3k	2.7k	2.0k	1.6k	1.1k	150	10.3k
David MacManus United Kingdom	57	6.4k 1.2×	3.3k 1.2×	791 0.4×	1.9k 1.2×	1.4k 1.3×	146	10.4k
Ernst‐Wilhelm Radue Switzerland	39	4.2k 0.8×	1.7k 0.6×	723 0.4×	1.0k 0.6×	1.5k 1.4×	117	7.3k
Tjalf Ziemssen Germany	52	4.8k 0.9×	2.6k 1.0×	847 0.4×	856 0.6×	1.6k 1.5×	466	10.9k
Peter Rudge United Kingdom	58	3.2k 0.6×	2.8k 1.1×	1.0k 0.5×	1.0k 0.6×	2.0k 1.9×	216	10.3k
Carlo Pozzilli Italy	69	10.0k 1.9×	4.1k 1.5×	1.1k 0.6×	2.3k 1.5×	1.5k 1.4×	385	14.8k
Vittorio Martinelli Italy	57	7.8k 1.5×	3.5k 1.3×	614 0.3×	2.1k 1.3×	1.8k 1.6×	282	10.9k
Patrick Vermersch France	54	6.8k 1.3×	4.6k 1.7×	832 0.4×	2.3k 1.5×	1.9k 1.7×	391	13.7k
Achim Berthele Germany	45	3.1k 0.6×	2.1k 0.8×	714 0.4×	826 0.5×	1.3k 1.2×	178	7.7k
Charles M. Poser United States	38	7.9k 1.5×	3.9k 1.5×	649 0.3×	2.2k 1.4×	1.3k 1.2×	181	12.6k
M. Clanet France	21	7.1k 1.4×	2.7k 1.0×	367 0.2×	1.7k 1.1×	1.1k 1.0×	49	9.2k

Countries citing papers authored by Douglas S. Goodin

Since Specialization

Citations

This map shows the geographic impact of Douglas S. Goodin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas S. Goodin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas S. Goodin more than expected).

Fields of papers citing papers by Douglas S. Goodin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas S. Goodin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas S. Goodin. The network helps show where Douglas S. Goodin may publish in the future.

Co-authorship network of co-authors of Douglas S. Goodin

This figure shows the co-authorship network connecting the top 25 collaborators of Douglas S. Goodin. A scholar is included among the top collaborators of Douglas S. Goodin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas S. Goodin. Douglas S. Goodin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Goodin, Douglas S.. (2024). Pathogenesis of multiple sclerosis: genetic, environmental and random mechanisms. Journal of Neurology Neurosurgery & Psychiatry. 95(11). 1002–1011. 5 indexed citations

Schippling, Sven, Paul O’Connor, Volker Knappertz, et al.. (2016). Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial. Journal of Neurology. 263(7). 1418–1426. 38 indexed citations

Schlaeger, Regina, Nico Papinutto, Valentina Panara, et al.. (2014). Spinal cord gray matter atrophy correlates with multiple sclerosis disability. Annals of Neurology. 76(4). 568–580. 143 indexed citations

Goodin, Douglas S.. (2014). The epidemiology of multiple sclerosis. Handbook of clinical neurology. 122. 231–266. 133 indexed citations

Wilson, Leslie, Lixian Zhong, Elizabeth Crabtree, et al.. (2014). Patient centered decision making: Use of conjoint analysis to determine risk–benefit trade-offs for preference sensitive treatment choices. Journal of the Neurological Sciences. 344(1-2). 80–87. 64 indexed citations

Corwin, Michael J., Howard L. Golub, Gary Cutter, et al.. (2013). Subcategory Analysis of Causes of Death in Patients with Multiple Sclerosis from a Large US Insurance Database (S30.007). Neurology. 80(7_supplement).

Goodin, Douglas S., Douglas Jeffery, Ludwig Kappos, et al.. (2013). Fingolimod Reduces Annualized Relapse Rate in Patients with Relapsing-Remitting Multiple Sclerosis: FREEDOMS II Study Subgroup Analysis (P07.102). Neurology. 80(7_supplement). 4 indexed citations

Nuwer, Marc R., Ronald G. Emerson, Gloria Galloway, et al.. (2012). Evidence-Based Guideline Update. Journal of Clinical Neurophysiology. 29(1). 101–108. 106 indexed citations

Goodin, Douglas S., George C. Ebers, Gary Cutter, et al.. (2012). Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study. BMJ Open. 2(6). e001972–e001972. 38 indexed citations

10.

Goodin, Douglas S., Anthony T. Reder, George C. Ebers, et al.. (2012). Survival in MS. Neurology. 78(17). 1315–1322. 178 indexed citations

11.

Goodin, Douglas S., Anthony Traboulsee, Volker Knappertz, et al.. (2011). Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis. Journal of Neurology Neurosurgery & Psychiatry. 83(3). 282–287. 71 indexed citations

12.

Goodin, Douglas S., Anthony T. Reder, George C. Ebers, et al.. (2011). Predictive value of baseline and short-term outcomes on mortality in multiple sclerosis: Data from the interferon beta-1b 21-year long-term follow-up study. 2. 1 indexed citations

13.

Okuda, Darin T., Ellen M. Mowry, A. Beheshtian, et al.. (2008). Incidental MRI anomalies suggestive of multiple sclerosis. Neurology. 72(9). 800–805. 392 indexed citations

14.

Goodin, Douglas S.. (2004). Disease-modifying therapy in MS: a critical review of the literature. Journal of Neurology. 251(S5). v3–v11. 10 indexed citations

15.

Oksenberg, Jorge R., Lisa F. Barcellos, Bruce Cree, et al.. (2004). Mapping Multiple Sclerosis Susceptibility to the HLA-DR Locus in African Americans. The American Journal of Human Genetics. 74(1). 160–167. 236 indexed citations

16.

Goodin, Douglas S.. (2000). Therapeutic developments in multiple sclerosis. Expert Opinion on Investigational Drugs. 9(4). 655–670. 12 indexed citations

17.

Goodin, Douglas S., et al.. (1999). Survey of multiple sclerosis in Northern California. Multiple Sclerosis Journal. 5(2). 78–88. 64 indexed citations

18.

Siedenberg, Ralf, Douglas S. Goodin, Michael J. Aminoff, Howard A. Rowley, & Timothy P. L. Roberts. (1996). Comparison of late components in simultaneously recorded event-related electrical potentials and event-related magnetic fields. Electroencephalography and Clinical Neurophysiology. 99(2). 191–197. 25 indexed citations

19.

Goodin, Douglas S., et al.. (1994). Late electromyographic activity following stretch in human forearm muscles: physiological role. Brain Research. 641(2). 273–278. 5 indexed citations

20.

Goodin, Douglas S. & Michael J. Aminoff. (1984). THE RELATIONSHIP BETWEEN THE EVOKED POTENTIAL AND BRAIN EVENTS IN SENSORY DISCRIMINATION AND MOTOR RESPONSE. Brain. 107(1). 241–251. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact